• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Oboyle Kevin C was granted 15,135 shares (SEC Form 4)

    5/14/25 5:06:40 PM ET
    $OM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $OM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    OBOYLE KEVIN C

    (Last) (First) (Middle)
    3052 ORCHARD DRIVE

    (Street)
    SAN JOSE CA 95134

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Outset Medical, Inc. [ OM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/14/2025 A 15,135(1) A $0.0 15,135 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents Restricted Stock Units ("RSUs") granted to the reporting person on May 14, 2025. Each RSU represents a contingent right to receive one share of common stock. These RSUs shall vest quarterly over three years, subject to the reporting person's continued service through the applicable vesting date.
    By: John L Brottem For: Kevin O'Boyle 05/14/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OM

    DatePrice TargetRatingAnalyst
    8/8/2024$6.00 → $3.00Outperform → Sector Perform
    RBC Capital Mkts
    6/21/2024$5.00 → $6.00Sector Perform → Outperform
    RBC Capital Mkts
    4/8/2024$6.00Buy
    BTIG Research
    4/5/2024$6.00Neutral → Buy
    CL King
    1/12/2024$14.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    10/13/2023$32.00 → $3.00Buy → Underperform
    BofA Securities
    8/17/2023Neutral
    CL King
    11/11/2022$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $OM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 4:53:46 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 4:26:01 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outset Medical Inc.

      SC 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      11/12/24 10:32:13 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chair and CEO Trigg Leslie sold $16,643 worth of shares (935 units at $17.80), decreasing direct ownership by 2% to 58,129 units (SEC Form 4)

      4 - Outset Medical, Inc. (0001484612) (Issuer)

      5/16/25 5:24:11 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SVP Operations and R&D Nash Marc sold $4,491 worth of shares (252 units at $17.82), decreasing direct ownership by 2% to 13,465 units (SEC Form 4)

      4 - Outset Medical, Inc. (0001484612) (Issuer)

      5/16/25 5:22:58 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • General Counsel Brottem John L. sold $7,057 worth of shares (396 units at $17.82), decreasing direct ownership by 3% to 11,273 units (SEC Form 4)

      4 - Outset Medical, Inc. (0001484612) (Issuer)

      5/16/25 5:21:39 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Leadership Updates

    Live Leadership Updates

    See more
    • Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

      SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

      5/14/25 9:00:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Masimo Announces Leadership Transition

      Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

      1/21/25 4:00:00 PM ET
      $MASI
      $NARI
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Outset Medical Names Business Leader Dale E. Jones to Board of Directors

      Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company reducing the cost and complexity of dialysis, today announced the appointment of Dale E. Jones to its Board of Directors. "Dale brings more than 30 years of experience in building diverse and dynamic teams to Outset at a time of exceptional growth for our team," said Chair and CEO Leslie Trigg. "He leads with purpose and deeply understands the role values and culture play in building high-performance organizations, critical traits as we focus on transforming dialysis." Mr. Jones is a Senior Advisor at Diversified Search Group, and previously served as its CEO for more than eight years. He began his career in banking

      4/25/22 4:00:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Financials

    Live finance-specific insights

    See more
    • Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

      SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2025. First Quarter and Recent Highlights Net revenue of $29.8 million grew 6% from the prior-year period.Tablo console revenue grew 23% from the fourth quarter.Recurring revenue consisting of Tablo consumables and services grew 20% over the prior-year period to $22.7 million. Outset shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments over a period of approximately 12 months.Gross ma

      5/7/25 4:02:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

      SAN JOSE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter 2025 after the close of trading on Wednesday, May 7, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on

      4/16/25 4:32:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter, Year-End Highlights Net revenue of $29.5 million in the fourth quarter and $113.7 million in 2024 were both ahead of the company's prior guidance and preannouncement in January.Gross margin of 36.5% (37.7% on a non-GAAP basis) in the fourth quarter increased 220 basis points sequentially from the third quarter and 11 percentage points from the fourth quarter of 2023. Gross margi

      2/19/25 4:03:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors

      SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board. "Kevin's over 20 years of healthcare leadership experience span roles as CFO of several publicly traded companies and as a board director of 6 public medical device companies," said Leslie Trigg, Chair and CEO. "His expertise in c

      5/14/25 9:00:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical to Present at RBC Global Healthcare Conference

      SAN JOSE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate at the RBC Capital Markets Global Health Care conference on Tuesday, May 20, 2025, at 10:30 a.m. Eastern time. The live and archived webcast of the session will be available on the "Investors" section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc.Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The

      5/9/25 9:00:00 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

      SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2025. First Quarter and Recent Highlights Net revenue of $29.8 million grew 6% from the prior-year period.Tablo console revenue grew 23% from the fourth quarter.Recurring revenue consisting of Tablo consumables and services grew 20% over the prior-year period to $22.7 million. Outset shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments over a period of approximately 12 months.Gross ma

      5/7/25 4:02:00 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    SEC Filings

    See more
    • SEC Form SD filed by Outset Medical Inc.

      SD - Outset Medical, Inc. (0001484612) (Filer)

      5/29/25 4:05:14 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 144 filed by Outset Medical Inc.

      144 - Outset Medical, Inc. (0001484612) (Subject)

      5/15/25 5:57:41 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.

      SCHEDULE 13G/A - Outset Medical, Inc. (0001484612) (Subject)

      5/15/25 4:30:10 PM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $OM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Outset Medical downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Outset Medical from Outperform to Sector Perform and set a new price target of $3.00 from $6.00 previously

      8/8/24 6:47:35 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Outset Medical upgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts upgraded Outset Medical from Sector Perform to Outperform and set a new price target of $6.00 from $5.00 previously

      6/21/24 6:53:06 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BTIG Research initiated coverage on Outset Medical with a new price target

      BTIG Research initiated coverage of Outset Medical with a rating of Buy and set a new price target of $6.00

      4/8/24 7:26:20 AM ET
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care